Navigation Links
Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
Date:6/2/2010

EAST HANOVER, N.J., June 3 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that a Phase III study of Afinitor® (everolimus) tablets plus best supportive care met its primary endpoint, showing the drug significantly extended progression-free survival, or time without tumor growth, in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3 (RAD001 In Advanced Neuroendocrine Tumors), is part of the largest clinical trial program of its kind.

Everolimus is approved under the trade name Afinitor® (everolimus) tablets for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib.

Pancreatic NET can grow aggressively and at time of diagnosis nearly 60% of all patients have advanced disease, meaning the cancer has spread to other parts of the body and has become more difficult to treat(1),(2). The median survival rate for patients with advanced pancreatic NET is 17 months(2). Currently, surgery and chemotherapy are the only approved treatment options for patients with advanced pancreatic NET(1).

"Everolimus was developed to inhibit the mTOR protein, which is a critical target in treating various cancers, including NET. Results from RADIANT-3 demonstrate that everolimus has the potential to become an important treatment option for patients with advanced pancreatic NET, where there is a major unmet need," said Herve Hoppenot, President, Novartis Oncology. "These study results will serve as the basis of worldwide regulatory filings for everolimus and bring us one step closer to our goal of offering these patients a new therapy."

Full results
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 Pharmaceutical and ... managing multiple products for the same indication. This can ... that want to prevent one of their brands from ... According to recent research by benchmarking firm, Best ... as independent brands rather than together as part of ...
(Date:2/27/2015)... , Feb. 27, 2015  Pomerantz LLP is ... Inc. ("Vitae" or the "Company") (NASDAQ: VTAE ... S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ... and certain of its officers and/or directors have violated ... of 1934.  On February 27, 2015, ...
(Date:2/27/2015)... WASHINGTON , Feb. 27, 2015  Following ... Means Committee that moved H.R. 284, the Medicare ... the American Association for Homecare (AAHomecare) released a ... quick action to pass the legislation. ... in the House Ways and Means Committee is ...
Breaking Medicine Technology:New Report Details How to Expand a Pharmaceutical Product Portfolio without Cannibalizing an Established Brand 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2
... Positive Results to Date Drive Decision to Expand its Proprietary ... ... AG, a leading,developer of antibody fragment therapeutics, today announced that the,company ... an extended,Series B venture round to expand its development pipeline. A ...
... 6 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) reported ... ended June 30, 2008 and provided an update,on the ... for the quarter and six month period ended June ... accepted in the United,States (GAAP), was $14.1 million and ...
Cached Medicine Technology:ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing 2ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing 3Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 2Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 3Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 4Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 5Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 6Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 7Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 8Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 9Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 10Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates 11
(Date:2/28/2015)... Santa Cruz, california (PRWEB) February 28, 2015 ... an ever growing number of practicing physicians as a way ... experience, training or education regarding Cannabis as medicine. Since the ... have been very few resources available to licensed physicians ... treatment to a patient. Dr. Deborah Malka in Santa ...
(Date:2/28/2015)... The Heart Fit Clinic started doing ... the machine. The Heart Fit Clinic is also selling ... franchise model. The goal is to scale the business ... To buy External Counterpulsation machines can be ... through this process and achieve the desired results. ...
(Date:2/28/2015)... 2015 Indosoft Inc , developers ... Asterisk, are pleased to announce the development of Q-Suite ... 5.8 versions of Q-Suite, this new version will include ... of new features to the leading edge call center ... 5.9 will add features to enhance security and protection. ...
(Date:2/28/2015)... St. Louis, MO (PRWEB) February 28, 2015 ... a leading provider of outsourced sales, marketing and ... announces their client, BIOTA Botanicals, is bringing its ... , Celebrated worldwide, BIOTA Botanicals’ products are specifically ... the herbal care experts, BIOTA is committed to ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 How ... Supportive? Strategic? , There are all kinds of ... To raise awareness of the advantages and applications ... PeopleKeys is launching a new product this spring ... better understand the connection between personality type, leadership, ...
Breaking Medicine News(10 mins):Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3
... and radiation significantly improved the 5-year overall survival of ... a phase III study published Nov. 4 in ... Nasopharyngeal carcinoma is endemic in Southern China ... primary treatment. Although the National Comprehensive Cancer Network (NCCN) ...
... 4 (HealthDay News) -- Over-the-counter "thyroid support" supplements commonly ... mostly ineffective and may pose a health threat, a ... amounts of two kinds of thyroid hormones -- triiodothyronine ... chopped up animal thyroid glands, according to senior investigator ...
... disclose an error when one occurs. While errors should be ... care delivery system is not and will never be perfect; ... In the study, "Nurses, Perceptions of Error ... 2012 issue of the Journal of Nursing Care Quality ...
... Souvenaid confirmed that daily intake of the nutritional intervention ... Results of the trial - called Souvenir II ... Clinical Trials in Alzheimer,s Disease (CTAD) in San Diego, ... MD, PhD, Professor of Cognitive Neurology and Director of ...
... , FRIDAY, Nov. 4 (HealthDay News) -- Delaying ... your chances of recovery, new research finds. A study ... six months of first experiencing herniated lumbar disc symptoms had ... longer to be treated. The patients in the study ...
... most important meal of the day. Don,t snack before supper; ... have been dropped on children for decades, and University of ... they quite often have a hard time applying them. In ... Fisher,s research notes that while people know the rules surrounding ...
Cached Medicine News:Health News:Concurrent chemo and radiation confers survival benefit in nasopharyngeal carcinoma patients 2Health News:Buyer, Beware of Over-the-Counter Thyroid Supplements: Study 2Health News:New study from NYUCN is the first to look at nursing error disclosure in nursing homes 2Health News:Nutritional intervention helps in mild Alzheimer's disease 2Health News:Timing May Be Key to Successful Back Surgery 2Health News:Food for thought: Contravening lay beliefs of eating at heart of our dietary disasters 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: